Dr. Zamarin on the Future Treatment Landscape of Gynecologic Malignancies

Dmitriy Zamarin, MD, PhD
Published: Friday, Oct 13, 2017



Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

According to Zamarin, the first drugs that will be approved will be more of the standard off-the-shelf treatments, such as immune checkpoint blockade or vaccines.

The adoptive T-cell therapies will be are more involved and more expensive, states Zamarin. The recent product that was approved from Novartis for the treatment of patients with leukemia is very expensive per treatment, which may become a limitation of choosing some of these therapies. If the therapies resolve in long-term disease stabilization or even cures of these patients, perhaps these types of treatments will justify the costs, explains Zamarin.
 
SELECTED
LANGUAGE


Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the future treatment landscape for patients with gynecologic malignancies.

According to Zamarin, the first drugs that will be approved will be more of the standard off-the-shelf treatments, such as immune checkpoint blockade or vaccines.

The adoptive T-cell therapies will be are more involved and more expensive, states Zamarin. The recent product that was approved from Novartis for the treatment of patients with leukemia is very expensive per treatment, which may become a limitation of choosing some of these therapies. If the therapies resolve in long-term disease stabilization or even cures of these patients, perhaps these types of treatments will justify the costs, explains Zamarin.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x